Tackling the Serious Global Challenges in Infectious Disease

Appili was created to deliver innovative drug development programs for unmet patient needs across a broad spectrum of infectious diseases

Appili Therapeutics Infectiou Disease Drug Development Program

Advancing infectious disease drug development programs to provide solutions to patients, doctors, and society.

Leadership team skilled in advancing programs with upside potential

Active partnering and in-licensing efforts to expand clinical programs and accelerate commercialization

Appili Therapeutics: Innovation Across a Broad Spectrum of Anti-Infectives

LATEST NEWS RELEASES

Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
11/15/2022
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023
11/10/2022
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
09/22/2022
Company Conference Room

LATEST EVENTS

Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
11/15/2022
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023
11/10/2022
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
09/22/2022